The annually American Society of Hematology (ASH) annual meeting is the biggest feast in this area.The 56th ASH annual meeting showed many important data related with lymphoma.Applied brentuximab vedotin as maintenance therapy after autologous stem cell transplantion,Hodgkin lymphoma (HL) patients acquired significant prolonged progression free survival (PFS).A phase Ⅰ study demonstrated that PD-1 inhibitor,nivolumab,has a high response in heavily treated HL,with ORR 87 ％,which has acquired the approval from FDA.BTK inhibitor,PI3K inhibitor,new CD20 antibodies,bcl-2 inhibitor and lenalidomide all are effective in relapsed or refractory chronic lympholytic leukemia (CLL) and non-Hodgkin' s lymphoma (NHL),but how to apply these new targeted drugs appropriately and combined with current chemotherapy regimens are quite difficult.CAR-T cells targeting CD19,CD20,CD30 or CD138 positive lymphomas are a kind of new cellular therapy,which has showed excellent efficacy.